Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year updateAngela Dispenzieri, Soon-Chai Low, Doug Chapman et al.|Orphanet Journal of Rare Diseases|2022Cited by 91
Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes SurveyJosé Nativi-Nicolau, D. Eric Steidley, Alfonso Siu et al.|JACC CardioOncology|2021Cited by 61
Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)Márcia Waddington‐Cruz, Daniel J. Lenihan, Jonas Wixner et al.|Neurology and Therapy|2021Cited by 48
Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year updateThomas H. Brannagan, Teresa Coelho, Annabel K. Wang et al.|Journal of Neurology|2022Cited by 36
Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delayTeresa Coelho, Cheng‐Yin Tan, Angela Dispenzieri et al.|Amyloid|2023Cited by 15